NAV

10-hydroxycamptothecin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
10-hydroxycamptothecin
DrugBank Accession Number
DB12385
Background

10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 364.357
Monoisotopic: 364.105921623
Chemical Formula
C20H16N2O5
Synonyms
Not Available
External IDs
  • NSC-107124

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when 10-hydroxycamptothecin is combined with Cinchocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Hydroxyquinolines / Pyranopyridines / Pyridinones / 1-hydroxy-2-unsubstituted benzenoids / Tertiary alcohols / Heteroaromatic compounds / Carboxylic acid esters / Lactams / Lactones / Azacyclic compounds
show 7 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Alcohol / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Camptothecin / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyranoindolizinoquinoline (CHEBI:81395)
Affected organisms
Not Available

Chemical Identifiers

UNII
9Z01632KRV
CAS number
19685-09-7
InChI Key
HAWSQZCWOQZXHI-FQEVSTJZSA-N
InChI
InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
IUPAC Name
(19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
SMILES
CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=CC1=C3)C2=O

References

General References
Not Available
KEGG Compound
C17939
PubChem Compound
97226
PubChem Substance
347828633
ChemSpider
87754
BindingDB
50008922
ChEBI
81395
ChEMBL
CHEMBL273862
ZINC
ZINC000003979155

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.331 mg/mLALOGPS
logP1.69ALOGPS
logP0.92Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)9.65Chemaxon
pKa (Strongest Basic)3.17Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area99.96 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity96.47 m3·mol-1Chemaxon
Polarizability37.51 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTOF , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0009000000-7740e8a79502c7590530
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0009000000-acb0fc91e1e6144e4dfb
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0006-0009000000-1435843a0ba5003a7004
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-0493000000-f0b1c94385d0a4241330

Drug created at October 20, 2016 22:10 / Updated at June 12, 2020 16:53